Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eqgSCfbwocfHgHyxmNQH

  ADVERTISEMENT  
April 11, 2013
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
  • FDG-PET sheds light on survival in non-small cell lung cancer
    Positive results on an FDG-PET scan may indicate poorer survival in patients with early-stage non-small cell lung cancer, according to findings presented at a cancer research meeting. Patients with the positive PET scan showed a median five-year survival of 67%, while survival for those with negative results was 80%. The method may help determine which patients should have adjuvant chemotherapy, researchers said. MedPage Today (free registration) (4/10) LinkedInFacebookTwitterEmail this Story
 
  Clinical News & Research 
  • PET/CT helps gauge patient response to neoadjuvant chemotherapy
    A study presented at a radiology meeting found that FDG-PET/CT has the potential to predict patient response following neoadjuvant chemotherapy for breast cancer. Researchers said the results suggest the assessment could be useful for guiding treatment decisions. The researchers used Sinn scores and two algorithms to measure patient response. An 88% change in maximum standardized uptake value is the appropriate cutoff to distinguish lesions that respond to treatment, they reported. AuntMinnie.com (free registration) (4/10) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Cell>Point reports promising findings for 99mTc-EC-G
    Radiopharmaceutical firm Cell>Point said findings from Phase I and IIa trials were promising for its technetium-99m-labeled ethylenedicysteine-glucosamine, an imaging agent used in diagnosing coronary artery disease. The company is planning a Phase IIb study to assess the diagnostic accuracy of the agent in identifying ischemia in patients at rest who have coronary artery disease. AuntMinnie.com (free registration) (4/10) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • AHRA backs breast density advocacy effort
    AHRA: The Association for Medical Imaging Management has announced its support for the Are You Dense Advocacy group, which aims to standardize the notification of breast density information. Fifteen breast density measures have been introduced this year in states, and a federal breast density bill is also expected to be revived, according to AHRA. AuntMinnie.com (free registration) (4/10) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Researchers create gold nanoparticles for biokinetic studies
    Researchers in Germany have developed radiolabeled gold nanoparticles for application in studies designed to evaluate how the particles function in biological systems. The gold radioisotope has a 186-day half-life, which makes it useful for long-term biokinetic studies, according to the report published in the Journal of Nanoparticle Research. Researchers said the nanoparticles can be stable for several hours, meaning they are useful for risk assessments. ChemicalWatch.com (free content) (4/10) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • FDA seeks input on effects of extreme weather on medtech
    The FDA is accepting comments through May 10 on the possible effects of natural disasters and extreme weather on the following: medical devices already being used in patient care; unused devices, parts or accessories; and manufacturing plants. A public meeting will also be held today to explore ways to better address manufacturing challenges tied to extreme weather. Clinica (subscription required) (4/8) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  From SNMMI 
  • Last chance to save on your SNMMI 2013 Annual Meeting registration!
    Today is the last day to take advantage of early-bird registration rates for the SNMMI 2013 Annual Meeting. More than 100 CE sessions, 1,300+ scientific posters, nuclear medicine review course, CT case review sessions and student technologist registry review await you in Vancouver, British Columbia. Register now. LinkedInFacebookTwitterEmail this Story
  • Now available! Nuclear Medicine Review Course online
    Getting ready to take the board exam? SNMMI's Nuclear Medicine Review Course consists of 14 lectures by world-renowned experts lecturing on the most critical topics in clinical nuclear medicine, including Physics & Instrumentation Pediatric Review, Endocrine Review PET/CT, Review of Gastrointestinal & Abdominal Imaging, Pulmonary Review, Immunotherapy Review, Review of Genitourinary System, Skeletal Review Tumor & Abscess Review, Review NRC Regulations Central Nervous System Review, and Cardiac Review Case Review. Get started today. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
To live is so startling it leaves little time for anything else."
--Emily Dickinson,
American poet


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.®  Legal Information